COMMUNIQUÉS West-GlobeNewswire

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
10/04/2025
– SRC recommended that the trial escalate to the next dose level of 30mg capsule – – No dose-limiting toxicities (DLT’s) or rash observed to date – MIAMI, April 10, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. ( [...]
Large Reductions in Suicide Risk, Attempts and Deaths Demonstrated by Three “Real World” Studies in Primary Care
10/04/2025
Shatterproof and The Bowman Family Foundation call for widescale adoption of Collaborative Care Model in primary care to reduce suicide rates and lower total healthcare costs for payers NORWALK, Conn., April 10, 2025 ( [...]
AccuStem Sciences, Inc. Announces Chairman Purchase of Shares
10/04/2025
LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of [...]
Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
10/04/2025
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of [...]
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)
10/04/2025
On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025 NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic [...]
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
10/04/2025
GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson’s disease models Enrollment update provided for Phase 1b study Phase 1b study ongoing to assess safety [...]
Dr. Mahmoud Aljurf, First Non-US Physician to win Weinberger Prize by American College of Physicians
10/04/2025
KFSHRC's pioneer recognised for groundbreaking work in hematology and stem cell research RIYADH, Saudi Arabia, April 10, 2025 (GLOBE NEWSWIRE) -- Dr. Mahmoud Aljurf, M.D., MACP, Director of the Adult Stem Cell [...]
Merakris Therapeutics Appoints Roger Ilagan to Chief Scientific Officer
10/04/2025
As CSO, Dr. Ilagan will continue to spearhead the advancement of cell-free biologic therapies from immunologically privileged tissues to regenerative medicine drugs for complex cutaneous wounds RESEARCH TRIANGLE PARK, N [...]
The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to a fine for a securities market information offence
10/04/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 10 APRIL 2025 at 13.15 EEST The Helsinki Court of Appeal sentenced a member of Orion's Board of Directors to [...]
Keros Therapeutics Announces Review of Strategic Alternatives
10/04/2025
Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process LEXINGTON, Mass., April 10, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage [...]
Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis
10/04/2025
The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET [...]
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema
10/04/2025
ZUG, Switzerland, April 10, 2025 (GLOBE NEWSWIRE) -- DIAMOND is the first and only pivotal trial program ever conducted with a topical treatment for diabetic macular edema (DME) Over 800 patients randomized in DIAMOND-1 [...]
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
10/04/2025
ROCKVILLE, Md., April 10, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025
10/04/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7AM CET Fagron to present its upgraded growth strategy and mid-term financial targets at its Capital Markets Day 2025 Fagron, the [...]
Record first-quarter revenue of €239 million, reflecting 14% topline growth
10/04/2025
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET Record first-quarter revenue of €239 million, reflecting 14% topline growth Fagron, the leading [...]
NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
09/04/2025
TORONTO and HAIFA, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) is pleased to provide a business update and reported financial [...]
Codexis Announces Byron Dorgan to Retire from Board of Directors
09/04/2025
REDWOOD CITY, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that Byron Dorgan [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
09/04/2025
ZUG, Switzerland, April 09, 2025 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to directors of the Company. Attachment Notification of managers' [...]
COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
09/04/2025
Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and [...]

Pages